This study is a first-in-human clinical trial testing a new treatment for rhegmatogenous retinal detachments. The new treatment called retinal thermofusion uses a special laser device called iSeelr™ during surgery. The benefit of the device is that it repairs retinal tears without needing a gas bubble making it quicker to recover from surgery. The study will help us determine how safe and well the device performs in repairing a retinal detachment in people.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
To assess the safety and performance of the investigational device, iSeelr™ System for the treatment of rhegmatogenous retinal detachments.
Timeframe: Assessment will take place before discharge on day of surgery and on days 1 and 2 post treatment
Assessment of intra-operative and post-operative adverse events
Timeframe: Up to 90 days post treatment